Commissioned by CDF in line with NICE TA563 and TA579 and CDF criteria.

Commissioned within the CDF as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, only if:
  •  they have a 17p deletion or TP53 mutation

Commissioned within the CDF as a second-line option for treating CLL in adults where:
  •  ibrutinib is their only suitable treatment option

Commissioning will transfer to NHSE 90 days following NICE publication

Commissioned by NHS England in line with NICE TA310.

Commissioned by NHSE in line with NICE TA536 recommendations.

Commissioned by NHS England in line with NICE TA333.

Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination encorafenib).

Commissioned by NHS England in line with NICE TA401.

Commissioned by NHSE in line with NICE TA571 as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer previously treated with crizotinib.

Commissioned by NHSE in line with NICE TA670 as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) that has not been previously treated with an ALK inhibitor in adults.
  •  This indication is funded by CDF until 27th April 2021

Cabometyx^®:

• Commissioned by NHSE in accordance with NICE TA463 and TA542 for the treatment of previously treated advanced renal cell carcinoma and untreated locally advanced or metastatic renal cell carcinoma respectively.


• Patients initiated on the Named Patient Programme should remain on free of charge stock for the duration of their treatment.

Cometriq^®:

• Commissioned in accordance with NICE TA516 for the first line treatment of medullary thyroid cancer.

Commissioned by NHS England in line with NICE TA395 and TA500.

Commissioned by CDF in line with CDF criteria and NICE TA529 and NHS England in line with NICE TA406 and TA422.

Commissioned by NHS England in line with NICE TA321, TA396 and TA544.

 TA396 and TA544 require BlueTeq prior approval.

In accordance with NICE TA595

Commissioned by NHS England in line with NICE TA425 and TA426.

Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination binimetinib).

Commissioned by NHSE in combination with Cetuximab as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment in line with NICE TA668.
  •  NOTE: Interim funding is via the CDF until April 6th 2021

Commissioned by NHSE in line with NICE TA643 for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

Commissioned via the Cancer Drugs Fund (CDF) in line with NICE TA644 for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if:
   • the disease is locally advanced or metastatic or surgery could cause severe health problems and
   • they have not had an NTRK-inhibitor before and
   • they have no satisfactory treatment options.

Commissioned by NHS England in line with NICE TA recommendations.

Commissioned by NHSE in line with NICE TA642 as monotherapy for treating relapsed or refractory FLT3‑mutation-positive acute myeloid leukaemia (AML) in adults.

Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant.

In accordance with CDF policy and NICE TA429, TA491 and TA502.

Commissioned in accordance with NICE TA359.

For haematology indications use generic drug, for gastrointestinal stromal tumours use Glivec^® brand.

Commissioned in line with CDF criteria and conditions of the managed access agreement in accordance with the recommendations in NICE TA630 for treating NTRK fusion-positive solid tumours.

Kisplyx^®:

• Commissioned by NHSE in accordance with NICE TA498 for the treatment of previously treated renal cell carcinoma in combination with everolimus.

Lenvima^®:

• Commissioned by NHSE in accordance with NICE TA535 for the treatment of differentiated thyroid cancer after radioactive iodine.


• Commissioned by NHSE in accordance with NICE TA551 for first line treatment of Child Pugh A locally advanced or metastatic hepatocellular carcinoma.

Commissioned by NHSE in line with NICE TA523 recommendations.

Commissioned by NHSE in line with the recommendations in NICE TA612.

Commissioned by NHS England in line with NICE TA241 and TA251.

Vargatef^®:

• Commissioned by NHS England in line with NICE TA347 for non-small-cell lung cancer.

 Ofev^®: 

• Commissioned by NHS England in line with NICE TA379 for idiopathic pulmonary fibrosis via specialist centres only.

Commissioned by NHSE for treating EGFR T790M mutation-positive advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA653, only if their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor.

Commissioned by NHSE for untreated EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA654.

Commissioned in accordance with NICE TA495 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

Patients inititated on the free of charge patient access programme should continue on free of charge treatment so long as they derive benefit.

Commissioned by CDF in line with NICE TA619 for treating hormone receptor-positive, HER2-negative, advanced breast cancer in combination with Fulvestrant.

Available under EAMS for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy

Commissioned by NHS England in line with NICE TA451.

Commissioned by NHS England in line with NICE TA488 and TA555.

Commissioned in accordance with NICE TA496 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

Commissioned by the CDF in accordance with NICE TA687 for treating hormone receptor-positive, (HER2)-negative, locally advanced or metastatic breast cancer in adults  
- This indication will transition to NHSE on 29th June 2021

Commissioned by NHS England in line with NICE TA386.
BlueTeq is required for this indication from 16/12/2020

Commissioned by NHS England in line with NICE TA474 and by CDF as per NICE TA535 and CDF policy.

For use in line with NICE TA169, TA179 and TA449.

 Blueteq prior approval required for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression (TA449).

Commissioned by NHSE in accordance with NICE TA512.

Commissioned by NHS England in line with NICE TA396.

Commissioned by |CDF in line with CDF criteria and NICE TA544.